Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients

NCT02904135 | Completed

• 1 other identifier: MBC 2.7
• Study Type: observational
• Target: 141
• Locations: 1 country
• Sites: 1

Brief Summary

To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and accurately detect CTCs in cancer patients. In order to facilitate the validation process, investigators will only focus on metastatic patients for whom CTCs supposedly present at higher abundance. Investigators propose to enroll cohorts of metastatic breast cancer patients. Blood samples will be collected from these patients before they start any new line of therapy as determined by their doctors. The specific aims are to isolate, enumerate and analyze the number and/or molecular information of circulating tumor cells in patient blood using microfluidic chip-based sorting, imaging, and molecular profiling techniques. Investigators will use this study to optimize diagnostic instrumentation, test blood processing protocols and CTC analysis algorithm. During this study investigators will collect patients' clinical information related to cancer, as well as the patients' survival status to validate the system's prognosis ability.

Conditions

Circulating Tumor Cells (CTCs)

Keywords

Circulating Tumor Cells

Outcome Measures

Primary Outcomes (1)

• Overall survival(OS)

  3 years

Study Arms (2)

first stage

During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.

second stage

During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.

Eligibility Criteria

• Age: 20 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

metastatic breast cancer (mBC) patients

You may qualify if:

• Provision of signed written informed consent before enrollment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study.
• Progressive and measurable metastatic breast cancer.
• Commencement of new anti-cancer chemotherapy or palliative care.
• ECOG performance status equal or less than grade 2.

You may not qualify if:

• Subject has received any investigational agent, not explicitly approved by MiCareo, within last one year.
• Subject being identified with any blood borne infectious disease.
• Subject has received anticancer chemotherapy within last one month. (not including hormone therapy, or target therapy)
• Pregnancy.

Sponsors & Collaborators

• MiCareo Taiwan Co., Ltd.: lead

Study Sites (1)

Keelung Chang Gung Memorial Hospital

Keelung, Taiwan

Location

MeSH Terms

Conditions

Neoplastic Cells, Circulating

Condition Hierarchy (Ancestors)

Neoplasm Metastasis; Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Chen Jui-Lin

  CEO

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 13, 2016
• First Posted: September 16, 2016
• Study Start: February 1, 2014
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: March 23, 2017

Record last verified: 2017-03

Locations

TW (1)